NuVasive — Q3 2018 Earnings Presentation
12 slides from NuVasive's earnings presentation, Oct 30, 2018
Slide 1: Q3 2018 Results Supplemental Presentation to Earnings Press Release
Q3 2018 Results Supplemental Presentation to Earnings Press Release October 30, 2018 Exhibit 99.2
Slide 2: Forward-Looking Statements
NuVasive, Inc. (“NuVasive,” “NUVA” or the “Company”) cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove co
Slide 3: Non-GAAP Financial Measures
Management uses certain non-GAAP financial measures such as non-GAAP earnings per share, non-GAAP net income, non-GAAP operating expenses and non-GAAP operating profit margin, which exclude amortization of intangible assets, business transition costs, purchased in-process research and development, o
Slide 4: Financial Performance
Q3 2018 Financial Performance GAAP diluted earnings per share of $0.30; Non-GAAP diluted earnings per share of $0.56, an increase of approximately 10% over prior year GAAP operating profit margin of 6.6% and non-GAAP operating profit margin of 15.6% Total revenue increased to $271.3 million, up 9.8%
Slide 5: Revenue Drivers
Q3 2018 Revenue Drivers U.S. Spinal Hardware Includes all Implants, Fixation and NuVasive Specialized Orthopedics (NSO) $146.1 7.0% Growth in case volume of more than 7%, and contributions from new product introductions, partially offset by approximately (2%) pricing pressure U.S. Surgical Support I
Slide 6: P&L Performance Non-GAAP Measures
Q3 2018 P&L Performance Non-GAAP Measures Q3 2018 Actuals Key Performance Factors Gross Margin 72.8% 70 bps below prior year primarily driven by the acquisition of SafePassage and investment in core NCS Sales, Marketing & Administration 51.6% 70 bps increase from prior year primarily driven by perfo
Slide 7: U.S. Revenue Trends
U.S. Revenue Trends U.S. Spinal Hardware Growth U.S. Biologics Growth *Includes U.S. Spinal Hardware and U.S. Surgical Support revenue, normalized for impact of Ellipse Technologies, SafePassage and Biotronic acquisitions **Includes clinical services revenue, normalized for impact of SafePassage and
Slide 8: West Carrollton Productivity
West Carrollton Productivity ~ Absorption Improvement and SKUs Insourced Improved Profitability Increased Utilization from Insourcing Procurement Productivity Improved Throughput FY’19 FY’18 Incremental Volume Savings on Unit Cost +130-150 bps Economies of Scale Machine & Labor Productivity + Varian
Slide 9: New Innovations and Partnerships
Q3 2018 New Innovations and Partnerships* *Some products not commercially released; NuVasive may not make these products available for commercial sale Surgical Automation Platform with 2D- and 3D-Navigation MAGEC X Early Onset Scoliosis Treatment Biologics Line Extension: Propel DBM, Amniotic Membra
Slide 10: Updated 2018 Full-Year Non-GAAP Guidance
Updated 2018 Full-Year Non-GAAP Guidance * Financial performance guidance as of July 31, 2018 ** Updated financial performance guidance as of October 30, 2018 Prior 2018 Guidance* Updated 2018 Guidance** $1.095B - $1.105B $1.105B - $1.110B 72.6% ~72.3% 55.9% 56.8% - 57.3% 16.7% 15.0% - 15.5% $2.37 -
Slide 11: 2018 Full-Year Financial Performance Guidance
2018 Full-Year Financial Performance Guidance* Financial Measures FY18 Guidance Key Performance Factors Revenue (as reported) $1,105M - $1,110M 7.6% to 8.1% growth Includes SafePassage contribution; ~$2M currency tailwind U.S. Spinal Hardware U.S. Surgical Support International 1) ~4% to ~5% YoY gro
Slide 12: For questions, contact investorrelations@nuvasive.com
For questions, contact investorrelations@nuvasive.com.